Related Experiment Videos
Adjuvant therapy for colorectal carcinoma.
Ryungsa Kim1, Yoshiyuki Yamaguchi, Tetsuya Toge
1Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan. rkim@hiroshima-u.ac.jp
Anticancer Research
|August 15, 2002
Summary
Adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) improves survival for Dukes
Area of Science:
- Oncology
- Gastroenterology
- Clinical Trials
Background:
- Adjuvant therapy for colorectal carcinoma has evolved significantly over the past two decades.
- Establishing standardized chemotherapy regimens requires evaluating rationale and survival benefits.
- Regional differences exist in treatment approaches and trial outcomes for colorectal cancer.
Purpose of the Study:
- To review the history and efficacy of adjuvant chemotherapy for colorectal carcinoma globally.
- To assess the survival benefits of various chemotherapy regimens and radiotherapy.
- To identify established and emerging standards for adjuvant treatment.
Main Methods:
- Review of randomized controlled trials (RCTs) and meta-analyses from the United States, Europe, and Japan.
- Analysis of survival data for different chemotherapy combinations and radiotherapy approaches.
- Comparison of adjuvant chemotherapy regimens against surgery alone and other treatment modalities.
Main Results:
- 5-fluorouracil (5-FU) plus leucovorin (LV) demonstrated survival benefit for Dukes' C colon carcinoma in Western trials.
- Combination therapy with mitomycin (MMC) and oral fluoropyrimidines showed survival benefit in Japanese trials.
- Preoperative radiotherapy proved superior to postoperative radiotherapy for advanced rectal carcinoma in preventing local recurrence.
Conclusions:
- Current standard adjuvant chemotherapy for Dukes' C colon carcinoma is 5-FU plus LV.
- Radiotherapy is beneficial for local control and survival in advanced rectal carcinoma.
- Further research is ongoing to compare novel combination therapies with established regimens.